TICKERNERD
Menu
ARDXARDXHealthcare · Biotechnology

ARDX Stock Forecast: Ardelyx, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$4.06
+3.84% on the day

The 11 Wall Street analysts covering Ardelyx, Inc. hold a median 12-month price target of $14 — +232.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$1.0B
Ticker Nerd rank
54 / 100
Median analyst target
$14
Analysts covering
11
Total return, dividends reinvested
1W
+1.5%
1M
−21.3%
YTD
−30.4%
1Y
−30.5%
From 52W high
−49.2%
From 52W low
+3.8%
$3.91
$7.99
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ardelyx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
97
Value
95
Volatility
73
Accruals
60
Growth
47
Size
45
Momentum
40
Revisions
29
Issuance
18

Quality (97): The business earns solid, repeatable profits on what it owns.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26ARDXHigh $18Median $14Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $8Median $14High $18

The green dot is the last close — the median target sits +232.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
10 Aug 2026CitigroupMaintainsBuy$14 → $11
7 Aug 2026BTIGMaintainsBuy$17 → $14
7 Aug 2026TD CowenMaintainsBuy$13 → $10
16 June 2026Ladenburg ThalmannAssumesBuy$16
23 Feb 2026WedbushReiteratesOutperform—
20 Feb 2026BTIGReiteratesBuy—
20 Feb 2026HC Wainwright & Co.MaintainsBuy—
29 Jan 2026BTIGReiteratesBuy—
21 Jan 2026WedbushMaintainsOutperform—
9 Jan 2026BTIGMaintainsBuy—
9 Jan 2026CitigroupMaintainsBuy—
9 Jan 2026Piper SandlerUpgradeOverweight—
4 Nov 2025Piper SandlerMaintainsNeutral—
3 Nov 2025CitigroupMaintainsBuy—
31 Oct 2025TD CowenMaintainsBuy—
6 Aug 2025Piper SandlerMaintainsNeutral—
5 Aug 2025Raymond JamesMaintainsOutperform—
5 Aug 2025WedbushMaintainsOutperform—
18 June 2025HC Wainwright & Co.AssumesBuy$10
2 May 2025CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ARDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Ardelyx, Inc. (ARDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.6×

Cheaper than 95% of US stocks

Price / sales
2.3×

Cheaper than 49% of US stocks

Price / book
6.8×

Cheaper than 16% of US stocks

EV / EBITDA
−31.5×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
23.8%

Higher than 74% of US stocks

Earnings growth (YoY)
23.8%

Higher than 62% of US stocks

Gross margin
95.2%

Higher than 98% of US stocks

Operating margin
−10.3%

Higher than 24% of US stocks

Net margin
−12.4%

Higher than 19% of US stocks

Returns & dividend
Return on equity
−38.6%

Higher than 24% of US stocks

Return on assets
−4.3%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ARDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARDXArdelyx, Inc.$1.0B
54
ODTXOdyssey Therapeutics, Inc.$977.9M
1
ANNXAnnexon, Inc.$1.0B
38
JANXJanux Therapeutics, Inc.$969.6M
71
SLDBSolid Biosciences, Inc.$967.2M
46
KURAKura Oncology, Inc.$964.0M
78
AVTXAvalo Therapeutics, Inc.$1.0B
42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ardelyx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARDX news & analysis

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

PRNewsWire · 14 Aug 2026negative

Levi & Korsinsky issued a notice informing investors of a pending investigation into Ardelyx (ARDX). The notice follows the company's stock closing at $4.00 on August 7, 2026, down 17.86%, after its second-quarter 2026 product revenue of $118.1 million and a loss of about $(0.07) per share both came in below consensus estimates.

Why it matters — ARDX watchers would care because the investigation notice adds a legal/regulatory element on top of the sharp single-day share decline triggered by weaker-than-expected second-quarter results.

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Seeking Alpha · 12 Aug 2026neutral

Ardelyx reported Q2 revenue up 31% year-over-year, driven by IBSRELA and XPHOZAH, but payer friction is limiting near-term monetization and led to a guidance cut. Management is addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and a larger sales force.

Why it matters — ARDX watchers would care because the company's strong underlying demand is being offset by payer and access hurdles that have prompted a guidance cut and raised near-term execution uncertainty.

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of Ardelyx, Inc.'s Q2 2026 earnings call. The item makes the call transcript available for review but contains no details of the actual results or discussion.

Why it matters — A transcript of the Q2 2026 earnings call gives investors and analysts direct access to management's commentary on the company's latest quarterly performance.

New Strong Sell Stocks for August 7th

Zacks Investment Research · 7 Aug 2026negative

Ardelyx, Inc. (ARDX) was added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026, along with ARDT and GPRE.

Why it matters — ARDX watchers would care because a Strong Sell rating from Zacks Investment Research signals a negative outlook for the stock based on their analysis.

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 7 Aug 2026negative

Ardelyx reported a second-quarter loss of $0.07 per share, wider than the Zacks Consensus Estimate of a $0.05 loss but narrower than the $0.08 per-share loss a year earlier. Revenue came in below analyst estimates.

Why it matters — ARDX watchers would note that the company's quarterly loss missed expectations, even though it improved from a year ago.

FAQ

Frequently asked questions about ARDX stock

What is the ARDX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Ardelyx, Inc. have a median 12-month price target of $14, with estimates ranging from $8 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARDX stock a buy right now?

Of the 11 analysts covering Ardelyx, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ardelyx, Inc. 54 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARDX?

As at 15 Aug 2026, Ardelyx, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).

Will ARDX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +232.5% from the last close, and Ticker Nerd's factor model ranks Ardelyx, Inc. 54 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARDX stock forecast for 2030?

No analyst covering Ardelyx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $18 over the next 12 months.

How has ARDX stock performed over the past year?

Ardelyx, Inc. returned -30.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ardelyx, Inc. do?

Ardelyx Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class medicines to address unmet medical needs in gastrointestinal and cardio-renal diseases.

What is the latest news on ARDX?

The most recent item we track (PRNewsWire, 14 Aug 2026): "Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)". Levi & Korsinsky issued a notice informing investors of a pending investigation into Ardelyx (ARDX). The notice follows the company's stock closing at $4.00 on August 7, 2026, down 17.86%, after its second-quarter 2026 product revenue of $118.1 million and a loss of about $(0.07) per share both came in below consensus estimates.

Company

About Ardelyx, Inc.

Ardelyx Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class medicines to address unmet medical needs in gastrointestinal and cardio-renal diseases. The company employs an innovative platform that identifies new biological mechanisms and pathways, enabling the creation of potent therapies designed to act locally in the gastrointestinal tract, thereby minimizing systemic side effects and drug-drug interactions common with traditional treatments. Its key products include IBSRELA (tenapanor), indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH (tenapanor), used to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to or intolerance of phosphate binders. Ardelyx Inc. targets patients with significant unmet needs in these therapeutic areas, advancing patient care through targeted, efficacious treatments. Founded in 2007 and headquartered in Waltham, Massachusetts, Ardelyx Inc. plays a vital role in the biopharmaceutical sector by delivering novel solutions for challenging medical conditions.

CEO Mr. Michael G. Raab · 489 employees · United States · https://www.ardelyx.com